返回列表Patent

TRPV1靶向药物组合物获得韩国国内专利

2021-12-08

Application Number: 10-2021-0006947

Title of Invention: 制药 composition for treating TRPV1 activation-mediated diseases

With the approval of this domestic 专利, RudaCure Inc. has taken one step closer to commercializing RCI002 for various pain conditions.

The company plans to continue expanding its 专利 portfolio in line with its 专利 strategy as it secures additional 管线s in the future.

返回列表